Trials / Not Yet Recruiting
Not Yet RecruitingNCT06063070
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
An Open, Multicenter, Exploratory Clinical Study of Fluzoparib in Combination With Bevacizumab for Maintenance Therapy After First-line Platinum-containing Chemotherapy in BRCA Wild-type Advanced Ovarian Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center Phase II study of fluzoparib combined with bevacizumab for maintenance therapy after first-line platinum-containing chemotherapy in patients with BRCA wild-type advanced ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib plus bevacizumab.
Conditions
- Ovarian Cancer
- High Grade Serous Adenocarcinoma of Ovary
- High Grade Endometrioid Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian-tube Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib Capsules | oral |
| DRUG | Bevacizumab | Injectable solution |
Timeline
- Start date
- 2023-10-18
- Primary completion
- 2025-01-31
- Completion
- 2027-10-30
- First posted
- 2023-10-02
- Last updated
- 2023-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06063070. Inclusion in this directory is not an endorsement.